The disease at stake begins with a plumbing failure deep inside the liver. Hepatocytes — the organ’s principal working cells — manufacture bile, a detergent-rich fluid that carries fats, cholesterol, and metabolic waste into the intestine through a delicate branching network of microscopic ducts. In cholestatic diseases such as primary biliary cholangitis and primary sclerosing cholangitis, those ducts are progressively destroyed or scarred shut, and the bile acids that give bile its cleaning power become trapped within liver tissue instead of flowing outward. Bile acids are amphipathic molecules, with one water-loving face and one fat-loving face; the same dual chemistry that lets them solubilize dietary fat also lets them puncture lipid membranes. At pathological concentrations they kill hepatocytes, summon inflammatory cells, provoke the growth of reactive duct-like structures collectively called the ductular reaction, and push scar-forming hepatic stellate cells into laying down collagen. Left unbroken, the cycle advances to cirrhosis and often ends in liver transplantation. Standard therapy relies on ursodeoxycholic acid, a gentler bile acid with protective properties, but many patients respond incompletely and no approved drug reliably arrests the scarring of primary sclerosing cholangitis — which is why cholestatic disease remains one of hepatology’s most stubborn problems.

Behind the scenes, the liver normally runs a self-correcting circuit that keeps bile acid levels inside a narrow, non-toxic band. It manufactures most of its bile acids from cholesterol, with the enzyme CYP7A1 serving as the rate-limiting throttle of the production line. Finished bile acids are exported out of hepatocytes into the canaliculi — the first channels of the biliary tree — by BSEP, the bile salt export pump, one of the most specialized transporters in the body. The farnesoid X receptor sits at the center of the loop as the liver’s bile acid sensor: a nuclear receptor that, when bound by bile acids, executes two complementary maneuvers. It suppresses CYP7A1, slowing the creation of new bile acids, and it reinforces BSEP, accelerating the expulsion of the ones already made. In a healthy liver this push-pull arrangement holds the bile acid pool in balance. In chronic cholestasis the circuit collapses — export is physically blocked, synthesis grinds on, and intracellular bile acid levels climb past the threshold at which membranes rupture and inflammation ignites.

To test whether Danning Tablet could repair that broken circuit, the Shanghai team built two complementary mouse models of cholestatic injury. In the first, animals were fed a diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine, abbreviated DDC, a compound that poisons the small intrahepatic bile ducts and provokes a chronic cholangiopathy complete with a vigorous ductular reaction — a widely accepted experimental stand-in for human intrahepatic cholestasis. In the second, the common bile duct was surgically ligated, producing the bile duct ligation, or BDL, model, in which bile backs up behind a physical obstruction and scars the liver within weeks — the classic representation of extrahepatic cholestasis. Into both settings the researchers introduced oral Danning Tablet and then systematically measured the four cardinal features of cholestatic damage: liver injury, inflammation, ductular proliferation, and fibrosis. Because the two models wound the liver through entirely different routes, one chemical and duct-centered, the other mechanical and obstructive, any treatment that worked in both was unlikely to be exploiting a model-specific artifact.

The blood chemistry of the treated animals told a clear story. Serum levels of alanine aminotransferase and aspartate aminotransferase — enzymes that pour into the bloodstream when hepatocytes die — fell significantly in both DDC-fed and bile-duct-ligated mice given the tablet, relative to untreated cholestatic controls. Total bilirubin, the yellow pigment whose accumulation produces the jaundice of obstructed bile flow, dropped as well, and so did total bile acids, the direct gauge of how much membrane-dissolving detergent was circulating. Under the microscope the improvement was equally striking. Livers from treated animals showed markedly reduced inflammatory infiltration, tracked in part through myeloperoxidase, an enzyme hauled by swarming neutrophils; far fewer of the chaotic duct-like structures that mark a runaway ductular reaction; and visibly diminished collagen deposition, the structural signature of fibrosis. The tablet, in short, did not merely blunt biochemical alarms — it quieted the tissue-level cascade that converts an obstructed liver into a scarred and failing one.

To understand how a multi-component herbal preparation could accomplish all of that, the team turned to transcriptomics, the systematic reading of which genes are active in diseased liver tissue. By profiling the thousands of genes deranged by cholestasis, identifying the subset restored to normal activity by Danning Tablet, and mapping the changes onto the Kyoto Encyclopedia of Genes and Genomes — a curated atlas of cellular pathways — the researchers found the disease signature converging on a single hub: bile acid metabolism, and within it, the FXR signaling pathway. Untreated cholestatic livers displayed the expected chaos among transporter and synthesis genes, while treated livers showed a coordinated return toward equilibrium, export machinery climbing as synthesis machinery cooled. The transcriptomic data implied something subtle and important: the tablet was not indiscriminately sedating the injured liver, but re-engaging its native regulatory circuitry — precisely the feedback loop that cholestasis had broken. Such pathway-level convergence is rare in herbal pharmacology, where extracts often scatter their effects across many systems at once.

The mechanism, spelled out in the study, runs along two coordinated arms. On the export side, FXR activation drove up expression of BSEP, enlarging the hepatocyte’s capacity to shuttle bile acids out of the cell and into the biliary tree for disposal. On the synthesis side, the same activated receptor clamped down on CYP7A1, throttling the conversion of cholesterol into fresh bile acids at its enzymatic source. With less being made and more being shipped out, the toxic bile acid burden inside liver cells shrank — and every downstream catastrophe that depends on that burden was gradually starved of fuel, from membrane-injured hepatocytes to the myeloperoxidase-marked neutrophil swarms they attract, from runaway ductular expansion to the collagen fibers laid down by activated hepatic stellate cells. The findings recast Danning Tablet’s traditional role in precise molecular language: not a vague anti-inflammatory tonic, but a restoration of bile acid homeostasis through the liver’s own thermostat, turned back on by the drug rather than overridden by it.

Correlation, however, is not causation, and herbal extracts have a long history of plausible mechanisms that dissolve under controlled scrutiny. To close that gap, the researchers repeated their experiments with guggulsterone, a plant-derived compound from the resin of the guggul tree, long used in Indian medicine and known to pharmacologists as a functional antagonist of the farnesoid X receptor. The logic was surgical: if the tablet works by switching FXR on, then forcing FXR off should cancel the benefit. That is exactly what happened. When guggulsterone was co-administered with Danning Tablet, the therapeutic effects were abrogated — bile acid homeostasis was no longer restored, serum injury markers rebounded, and the protection against inflammation, ductular reaction, and fibrosis evaporated. Because the experiment manipulates the receptor directly rather than merely observing associations, it establishes the tablet’s action as FXR-dependent rather than incidental, the kind of mechanistic proof that clinicians and regulators demand before a traditional remedy can be treated as a genuine drug candidate.

The result lands at a moment when FXR has become one of the most sought-after drug targets in hepatology. Synthetic FXR agonists such as obeticholic acid have already reached patients in some cholestatic settings, but their use is constrained by tolerability problems, and effective options for advanced disease remain scarce. A traditional Chinese medicine tablet that is already manufactured, already prescribed across China, and now demonstrably active on the same receptor axis could offer an accessible alternative or complement — if the mouse findings translate. The caveats are real: murine models cannot fully reproduce the autoimmune underpinnings of human primary biliary cholangitis or primary sclerosing cholangitis, the rodent bile acid pool differs from the human one, and neither dosing nor long-term safety in patients has been established. The study was supported by the National Natural Science Foundation of China and a Shanghai academic research studio honoring senior traditional Chinese medicine physicians, and it was carried out in collaboration with Shanghai Hutchison Pharmaceuticals Co., Ltd., a detail that signals industrial appetite for carrying the finding toward clinical evaluation.

Beyond the immediate promise for cholestatic patients, the study doubles as a template for how traditional medicine can be interrogated with modern molecular tools. Rather than accepting or dismissing a multi-herb formula wholesale, the team isolated its mechanism, verified it across two mechanistically distinct disease models, and then erased it with a single targeted antagonist — the same evidentiary logic used to validate any small-molecule drug. The natural next questions follow directly: which individual ingredients within the tablet bind or activate FXR, whether the therapy can benefit patients already taking ursodeoxycholic acid, and whether restoring bile acid homeostasis early enough can prevent fibrosis from ever taking root. For now the picture remains preclinical, but it is an unusually complete one. A remedy that has sat in Chinese hospital pharmacies for generations turns out to speak fluent molecular biology — and the language it speaks, FXR signaling, is one that liver medicine is currently listening to with great intensity.